Skip to content
Cover: nephrology consultation with a kidney model and IV line

KDSTEM inj.: urine-derived stem cells and Klotho for chronic kidney disease

EHL Bio's renal cell therapy candidate

Quick answer

KDSTEM inj. is EHL Bio's cell therapy candidate using the patient's own urine-derived mesenchymal stem cells, given as repeat intravenous infusions for chronic kidney disease. Its scientific hook is that these cells express Klotho, an anti-ageing protein with antioxidant, anti-senescence, angiogenic and metabolic-regulating roles. It sits in preclinical and early clinical development.

Key facts

Product
KDSTEM inj.
Cell type
Autologous urine-derived MSC
Key protein
Klotho (anti-ageing/antioxidant)
Target indication
Chronic kidney disease
Administration
Repeat IV infusion

Urine-derived cells: a non-invasive source

Collecting cells from urine is entirely non-invasive, unlike liposuction or bone marrow aspiration. The patient simply provides a urine sample and the lab isolates urothelial-lineage cells with stem cell properties for expansion.

The Klotho protein and kidney protection

Klotho is produced mainly in the kidney and its levels typically fall in chronic kidney disease. The mechanistic hypothesis is that cells expressing high Klotho may reduce oxidative stress and renal fibrosis — the two engines of progressive kidney decline.

Not yet standard care for chronic kidney disease

It must be stressed that KDSTEM is not standard care for CKD. Guideline therapy remains blood pressure and diabetes control, ACEi/ARB and SGLT2 inhibitors, plus stage-appropriate diet. Patients should never stop existing medication to pursue cell therapy.

Use the kidney planner before your consultation

If you are exploring options, our site's kidney planning tool estimates CKD stage from eGFR or creatinine and drafts a preliminary plan with questions to raise with your doctor. Always have your nephrologist review that plan before acting on it.

Frequently asked questions

  • Can KDSTEM replace dialysis?

    No. Patients on dialysis must continue as prescribed. Cell therapy is investigational and adjunctive, not a replacement for renal replacement therapy.

  • Can stem cells really come from urine?

    Yes. Published research shows urine contains shed urothelial-lineage cells that can be cultured and display mesenchymal stem cell-like properties.

  • How many sessions are needed?

    The protocol calls for repeat dosing; the actual number depends on disease stage and physician assessment, not on advertised numbers.

  • When would kidney markers change?

    If change occurs, it is usually assessed via eGFR, proteinuria and clinical status over 3-6 months, with follow-up testing set by the physician.

Share this page

Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.

Back to categories

Related topics: Cell drug pipeline · Kidney, liver, heart, lung

See all in this category